• Profile
Close

Results of a prospective randomized, open-label, noninferiority study of tbo-filgrastim (Granix) versus filgrastim (Neupogen) in combination with plerixafor for autologous stem cell mobilization in patients with multiple myeloma and non-hodgkin lymphoma

Biology of Blood and Marrow Transplantation Sep 18, 2017

Bhamidipati PK, et al. - For stem cell mobilization in patients with multiple myeloma (MM) and non-Hodgkin lymphoma (NHL), the first prospective randomized trial compared the safety and efficacy of tbo-filgrastim in combination with plerixafor with that of filgrastim in combination with plerixafor. This study found the tbo-filgrastim and filgrastim arms similar in all secondary endpoints. As compared to reference filgrastim when used for stem cell mobilization in patients with MM and NHL, tbo-filgrastim was not inferior in efficacy and had a similar safety. Results suggested the safe use of Granix instead of Neupogen for stem cell collection in patients undergoing autologous hematopoietic stem cell transplantation (auto-HSCT) for MM or NHL.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay